InsidersTradesSigma
Total declarations
Companies
▲ Purchases (17 ops.)
▼ Sales (4 ops.)
Insider track record
OtherDisclosed buys
17
Disclosed sells
4
T+90 hit rate
67%
T+90 mean return
+10.2%
Across 9 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by Fairmount Funds Management LLC. Officer active across 10 companies, notably Viridian Therapeutics, Inc.\DE. In total, 45 disclosures have been published. Breakdown: 17 buys · 4 sells. Total volume traded: €572.3m. Activity tracked since 21 September 2021. The latest transaction was disclosed on 7 August 2026 (Levée d'options). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Fairmount Funds Management LLC
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations45 total
31,838 shares@ US$17.000.0053% mcap0.4% of flowCommon StockSEC:0001104659-26-094087:0
10,370 shares@ US$43.850.0045% mcap0.3% of flowCommon StockSEC:0001104659-26-094087:1
853,450 shares@ US$14.500.60% mcap40.8% of flowOrdinary SharesSEC:0001104659-26-085113:0
Canonical exit: 14 Oct 2026 (T+90)
666,680 sharesCommon StockSEC:0001104659-26-076967:0
4,684,781 sharesCommon StockSEC:0001104659-26-076967:1
150,000 shares@ US$20.00100.0% of flowCommon StockSEC:0001104659-26-038546:0
Canonical exit: 29 Jun 2026 (T+90)
7,000,000 shares@ US$34.6688.8% of flowCommon StockSEC:0001104659-26-038057:1
7,000,000 sharesCommon StockSEC:0001104659-26-038057:0
5,809,000 shares0Common StockSEC:0001193125-26-047535:0
1,750,000 shares@ US$76.3099.3% of flowCommon StockSEC:0001104659-26-005921:0
3,500,000 shares@ US$36.4029.8% of flowCommon StockSEC:0001104659-26-005924:0
1,360,000 shares@ US$13.41100.0% of flowOrdinary SharesSEC:0001104659-25-119320:0
Canonical exit: 4 Mar 2026 (T+90)
454,545 shares@ US$22.0013.6% of flowCommon StockSEC:0001104659-25-102606:0
Canonical exit: 21 Jan 2026 (T+90)
316,219 shares@ US$19.0066.5% of flowCommon StockSEC:0001104659-25-098362:0
Canonical exit: 5 Jan 2026 (T+90)
1,333,126 shares@ US$9.14100.0% of flowCommon StockSEC:0001104659-25-097921:0
333,340 shares@ US$15.0042.4% of flowCommon StockSEC:0001104659-25-091747:0
2,777,777 shares@ US$9.008.3% of flowCommon StockSEC:0001104659-25-067758:0
Canonical exit: 8 Oct 2025 (T+90)
1,600 shares@ US$7.800.0% of flowCommon StockSEC:0001104659-25-058580:0
160,000 sharesCommon StockSEC:0001213900-24-101116:0
62,146 shares0Common StockSEC:0001104659-24-105106:0
1,600,000 shares@ US$18.7542.9% of flowCommon StockSEC:0001104659-24-100769:0
Canonical exit: 12 Dec 2024 (T+90)
41,130 sharesCommon StockSEC:0001104659-24-100766:0
41,130 sharesCommon StockSEC:0001104659-24-100330:0
275,000 shares@ US$23.00100.0% of flowCommon StockSEC:0001213900-24-078633:0
1,500,000 sharesCommon StockSEC:0000950170-24-072639:0
25 of 45 declarations
About Fairmount Funds Management LLC
Fairmount Funds Management LLC is an insider and director of Cogent Biosciences, Inc., Viridian Therapeutics, Inc.\DE, Dianthus Therapeutics, Inc. /DE/, Spyre Therapeutics, Inc., Zenas BioPharma, Inc. and Apogee Therapeutics, Inc. The declarant has 42 filings in total. Among the sampled recent filings, from 2021-09-23 to 2026-06-23, buy amounts are EUR 128312391 and sell amounts are EUR 433150492, and the modal transaction nature is Acquisition.
